NCT04012866

Brief Summary

Cognitive impairments have severe impact on functional recovery and quality of life after stroke. Current evidence indicated that combining exercise and cognitive training may provide additional benefits on cognition in stroke. This study aims to investigate the effects and mechanisms of two combined methods of computer-based cognitive training with physical exercise in stroke patients with cognitive impairments.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Aug 2018

Typical duration for not_applicable stroke

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 30, 2018

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 20, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

July 9, 2019

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

September 9, 2020

Status Verified

June 1, 2020

Enrollment Period

3.3 years

First QC Date

May 20, 2019

Last Update Submit

September 8, 2020

Conditions

Keywords

Cognitive RehabilitationAerobic ExerciseComputerized Cognitive Training

Outcome Measures

Primary Outcomes (26)

  • Change scores of Mini-Mental State Exam (MMSE)

    The Mini-Mental State Exam (MMSE) is used to screen patients for cognitive impairment, track changes in cognitive functioning over time, and often to assess the effects of therapeutic agents on cognitive function. Its range of total score is 0-30 with higher values indicating better cognitive function.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of the Montreal Cognitive Assessment (MoCA).

    The Montreal Cognitive Assessment (MoCA) will be used to assess general cognitive functions. It examines several cognitive domains with a total score of 30 and higher values indicate better cognitive functions. The MoCA has been shown to be a valid and promising tool to evaluate the global cognitive function in patients with stroke. The psychometric properties of MoCA are good to excellent for patients with cerebrovascular diseases.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Wechsler Memory Scale - Third Edition (WMS-III)

    Several subtests of Wechsler Memory Scale - Third Edition (WMS-III) including Faces Recognition (total scale=48), Verbal Paired Associates (total scale = 32), Word Lists (total scale = 48), and Spatial Span (total scale=32) will be used to assess the immediate, delayed, and working memory tests. For each subtest, a higher number indicates better performance in memory function. The raw score of subtests will also be transferred to standardized Z scores and summed to represent an index of general memory function.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Wechsler Adult Intelligence Scale - Third Edition (WAIS-III)

    The Wechsler Adult Intelligence Scale - Third Edition (WAIS-III) is developed to measure an individual's intelligence level. The Digit Symbol-Coding (score range 0-133) and Matrix Reasoning (range 0-26) subtests will be used.A higher score indicating better performance. The raw score of each subtest will also be transferred to standardized Z scores and summed to represent an index of general cognitive function.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Useful Field of View (UFOV)

    The UFOV is a computer-based visual test containing three subtests: visuomotor processing speed, divided attention, and selective attention (Ball, Edwards, \& Ross, 2007). The UFOV has been shown to have good test-retest reliability and validity to assess patients with stroke (George \& Crotty, 2010).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Stroop Color-Word Test

    The Stroop Color-Word test assesses the abilities of selective attention, inhibition and executive function. The participants will be tested under congruent and incongruent conditions. In the congruent condition, the participant will name the color ink of a word which is consistent with the written color name; whereas in the incongruent condition the participant will name the color ink differs from the written color name. In both conditions, the number of colors correctly named within 45 seconds will be measured and the performance in the congruent condition will be compared with the incongruent condition (Quaney et al., 2009).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Dual-Task test

    The Dual-Task test evaluates the ability of set-shifting. Participants will sit and perform the box and block test (BBT) or walk 10 meters while doing secondary cognitive or motor tasks. Two cognitive secondary tasks will be performed by the participants: (1) arithmetic task: participants will be asked to perform serial subtractions by 7 starting from 100 or random two-digit numbers (e.g., Baetens et al., 2013); (2) tone discrimination task: participants will be presented a number of low and high-pitched tones and they will respond to either the high or low-pitched tones during the trial. Both cognitive task performances will be recorded and the results will be compared to single cognitive task performance. In addition to the cognitive dual-task, participants will perform a motor task (e.g., holding a cup of water) while walking.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Timed Up and Go Test (TUG)

    The TUG assesses the dynamic balance ability and mobility. The participants will be required to stand up from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. The test-retest reliability of TUG on individuals with stroke was excellent (Ng \& Hui-Chan, 2005).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Six-Minute Walk Test (6MWT)

    The 6MWT measures the maximum distance walked over 6 minutes, which assess the endurance and mobility level of the participants. The participants could rest as needed during the course of the test. The test-retest reliability and responsiveness has been established to be high for patients with chronic stroke (Fulk, Echternach, Nof, \& O'Sullivan, 2008).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Mobility Level

    Accelerometers will be used to provide an objective measure of the amount of arm movements in real-life situations. The participants will be asked to wear an Actigraphy activity monitor (ActiGraph, Shalimar, FL, USA) on both wrists for 3 consecutive days before and after training to measure the number of moves each minute, and the average counts of move per minute. The participants will be required to wear the device during the day except for doing water-based activities, such as bathing or swimming.The use of actigraphy to measure arm use and physical activity has been established for patients with stroke (Freedson, Melanson, \& Sirard, 1998; Maguire et al., 2012).

    Baseline, posttest (an expected average of 3 months)

  • Change scores of International Physical Activity Questionnaires (IPAQ)

    The short form version of International Physical Activity Questionnaires (IPAQ) assesses sitting, walking, moderate-intensity activities and vigorous intensity activities. Frequency (measured in days per week) and duration (time per day) are collected separately and transferred to MET-minutes values for each specific type of activity. A combined total physical activity MET-min/week can be computed as the sum of Walking + Moderate + Vigorous MET-min/week scores. Higher total scores indicated more health-related activities.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Fugl-Myer Assessment (FMA)

    The upper limb subscale of the Fugl-Myer Assessment (FMA-UE) assesses the motor impairments of upper limbs after stroke. The FMA-UE contains 33 movements with a score range from 0 to 66. A higher score indicated better motor recovery in upper limbs.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Rivermead Mobility Index (RMI)

    The Rivermead Mobility Index (RMI) evaluates the participant's functional mobility, balance, gait and walking ability. It contains a 15-item scale which includes 14 questions and one direct observation, with a total of score of 15 and higher scores indicating better mobility performance.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Muscle Strength

    We will evaluate isometric knee flexors and extensors muscle strength using handheld dynamometer. Also, we will use hand dynamometer to measure grip strength of the affected and less affected hand while the participant is seated, with the elbow at 90-degree flexion. We will record the mean value of 3 attempts.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Functional Independence Measure (FIM)

    The FIM assesses the dependence level of individuals with stroke to perform 18 activities (13 motor and five cognitive tasks) in daily living. The score ranges from 18 to 126 and higher scores demonstrate greater independent participation in daily activities (Ottenbacher, Hsu, Granger, \& Fiedler, 1996). The FIM has good interrater reliability and validity (Hsueh, Lin, Jeng, \& Hsieh, 2002).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Lawton Instrumental Activities of Daily Living Scale (Lawton IADL)

    The Lawton IADL scale evaluates 8 activities with a score range from 0 to 8 (higher indicate better function). The inter-rater reliability and validity of the Lawton IADL have been established to be moderate to high for community-dwelling older adults (Graf, 2008; Lawton \& Brody, 1969).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Stroke Impact Scale (SIS)

    The SIS contains 59 items measuring eight domains, including strength, hand function, ADL/IADL, mobility, communication, emotion, memory/thinking, and participation, with a single item assessing perceived overall recovery from stroke. The total score is the average of the domain scores, and the domain scores are the averages of the item scores (1-5), and higher scores indicate better function or QOL.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of EuroQol-5D Questionnaire (EQ-5D)

    The quality of life will be assessed by the EQ-5D questionnaire which comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has three levels: no problems, some problems, extreme problems. The score has been shown to be reliable and valid (Greiner et al., 2003).

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Community Integration Questionnaire (CIQ)

    The social participation level will be assessed with the Community Integration Questionnaire (CIQ).It contains 15 items to evaluate the degree of integration into each of the three area of family, social network, and productive activities. The total scores range from 0 to 29 with larger numbers indicating better integration.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Geriatric Depression Scale (GDS)

    The Geriatric Depression Scale (GDS) - 15 items version is a self-administered questionnaire used to evaluate mood and depressive symptoms. The scores range is 0-15 and a score of 5 or greater taken as a possible indicator of depression.

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Task-based Electroencephalogram (EEG)

    The Task-based EEG will be collected when participants perform the n-back task before and after the intervention program to examine the effects of training on neural plasticity.

    Baseline, posttest (an expected average of 3 months)

  • BDNF val66met genotype

    Saliva samples will be collected at baseline to determine the Brain-Derived Neurotrophic Factor (BDNF) val66met genotype.

    Baseline

  • Serum BDNF level

    Blood samples will be collected at baseline and after the intervention programs. The blood tests will include serum BDNF level, antioxidative markers, HbA1C level, and Plasma lipid level. Serum BDNF will be quantified using an enzyme-linked immunosorbent assay (Human BDNF Quantitative Immunoassay, DBD00, R\&D Systems) according to the manufacturer's instructions. This sandwich ELISA is set in order to measure natural and recombinant human mature BDNF in serum and plasma. All assays will be performed on F-bottom 96-well plates (Nunc, Wiesbaden, Germany).

    Baseline, posttest (an expected average of 3 months)

  • Total antioxidant capacity (TAC)

    Blood samples will be collected at baseline and after the intervention programs. The blood tests will include BDNF level, antioxidative markers, HbA1C level, and Plasma lipid level. Antioxidative markers will be used to reflect the changes on oxidative stress. In particular, we will be analyzing the total antioxidant capacity (TAC).

    Baseline, posttest (an expected average of 3 months)

  • Glucose indicator

    Blood samples will be collected at baseline and after the intervention programs. The blood tests will include BDNF level, antioxidative markers, HbA1C level, and Plasma lipid level. HbA1C level will be tested to investigate the relationships between blood glucose level and aerobic exercise.

    Baseline, posttest (an expected average of 3 months)

  • Plasma lipid level

    Blood samples will be collected at baseline and after the intervention programs. The blood tests will include BDNF level, antioxidative markers, HbA1C level, and Plasma lipid level. The cholesterol ratio (total cholesterol divided by high-density lipid) will be evaluated to reflect the lipid level in the blood.

    Baseline, posttest (an expected average of 3 months)

Secondary Outcomes (2)

  • Change scores of Caregiver Strain Index (CSI)

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

  • Change scores of Caregiver Burden Scale(CBS)

    Baseline, posttest (an expected average of 3 months), follow-up (up to 9 months)

Study Arms (3)

SEQ (sequential training group)

EXPERIMENTAL

The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.

Behavioral: Aerobic exercise trainingBehavioral: Computerized cognitive training

DUAL (dual training group)

EXPERIMENTAL

The dual training group (DUAL) will receive aerobic exercise training and computerized cognitive training simultaneously. All participants will receive a training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.

Behavioral: Aerobic exercise trainingBehavioral: Computerized cognitive training

CI (control intervention group)

ACTIVE COMPARATOR

The control intervention group (CI) will receive a control training session for 60 minutes per day, two or three days per week for 12-18 weeks, a total of 36 training sessions.

Behavioral: Control training

Interventions

The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.

DUAL (dual training group)SEQ (sequential training group)

The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.

DUAL (dual training group)SEQ (sequential training group)

The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.

CI (control intervention group)

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ischemic or hemorrhagic stroke occurring at least 6 months prior to enrollment
  • Age range from 20 to 90 years
  • MMSE score \< 28, or MoCA score \< 25
  • Self- or informant-reported memory or cognitive complaints or Clinical dementia rating (CDR) scale ≤ 0.5
  • Able to follow the study instruction
  • Adequate cardiopulmonary function to perform aerobic exercise
  • Able to walk with or without assistive devices

You may not qualify if:

  • Unstable medical history (e.g., recent myocardial infarction) that might limit participation
  • Concomitant with other neurological disorders (e.g., Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis)
  • Current participation in another interventional trial

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Kaohsiung Municipal Siaogang Hospital

Kaohsiung City, 482, Taiwan

RECRUITING

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 833, Taiwan

RECRUITING

Far Eastren Memorial Hospital

New Taipei City, 220, Taiwan

RECRUITING

Chang Gung Memorial Hospital

Taoyuan District, 333, Taiwan

RECRUITING

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Study Officials

  • Ching-yi Wu, ScD

    Chang Gung Memorial Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ching-yi Wu, ScD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2019

First Posted

July 9, 2019

Study Start

August 30, 2018

Primary Completion

December 31, 2021

Study Completion

December 31, 2021

Last Updated

September 9, 2020

Record last verified: 2020-06

Locations